Antibody Fc variants

Number of patents in Portfolio can not be more than 2000

United States of America Patent

PATENT NO 8969526
APP PUB NO 20120251531A1
SERIAL NO

13431489

Stats

ATTORNEY / AGENT: (SPONSORED)

Importance

Loading Importance Indicators... loading....

Abstract

See full text

The invention relates to engineered polypeptides comprising Fc variants and their uses. More specifically, Fc variants are described exhibiting reduced effector function. These variants cause a benefit for a patient suffering from a disease which could be treated with an antibody for which it is desirable to reduce the effector function elicited by antibodies.

Loading the Abstract Image... loading....

First Claim

See full text

Family

Loading Family data... loading....

Patent Owner(s)

Patent OwnerAddress
ROCHE GLYCART AG8952 SCHLIEREN-ZUERICH

International Classification(s)

Inventor(s)

Inventor Name Address # of filed Patents Total Citations
Baehner, Monika Munich, DE 27 554
Jenewein, Stefan Neustadt/Weinstrasse, DE 34 316
Kubbies, Manfred Penzberg, DE 27 350
Moessner, Ekkehard Kreuzlingen, CH 194 2920
Schlothauer, Tilman Penzberg, DE 65 494

Cited Art Landscape

Load Citation

Patent Citation Ranking

Forward Cite Landscape

Load Citation

Maintenance Fees

Fee Large entity fee small entity fee micro entity fee due date
11.5 Year Payment $7400.00 $3700.00 $1850.00 Sep 3, 2026
Fee Large entity fee small entity fee micro entity fee
Surcharge - 11.5 year - Late payment within 6 months $160.00 $80.00 $40.00
Surcharge after expiration - Late payment is unavoidable $700.00 $350.00 $175.00
Surcharge after expiration - Late payment is unintentional $1,640.00 $820.00 $410.00